Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Artia Global Partners LP

Artia Global Partners LP boosted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 88.6% during the 4th quarter, Holdings Channel reports. The fund owned 205,090 shares of the company’s stock after acquiring an additional 96,367 shares during the quarter. Dianthus Therapeutics comprises 1.2% of Artia Global Partners LP’s portfolio, making the stock its 15th largest holding. Artia Global Partners LP’s holdings in Dianthus Therapeutics were worth $8,452,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new stake in Dianthus Therapeutics in the 4th quarter valued at approximately $40,000. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new stake in Dianthus Therapeutics in the 3rd quarter valued at approximately $64,000. Royal Bank of Canada increased its position in Dianthus Therapeutics by 36.9% in the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after acquiring an additional 542 shares during the period. Finally, Quarry LP acquired a new stake in Dianthus Therapeutics in the 4th quarter valued at approximately $99,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DNTH has been the topic of several analyst reports. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the company a “buy” rating in a research note on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $81.89 on Thursday. The stock has a fifty day moving average price of $86.81 and a two-hundred day moving average price of $66.00. The firm has a market cap of $4.48 billion, a P/E ratio of -19.83 and a beta of 1.18. Dianthus Therapeutics, Inc. has a 1 year low of $16.64 and a 1 year high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 8,224 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the completion of the sale, the executive vice president directly owned 8,224 shares of the company’s stock, valued at $738,844.16. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 149,121 shares of company stock valued at $12,635,454. Corporate insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.